論文・総説 - 末永　光邦

分割表示  324 件中 201 - 220 件目  ／  全件表示 >>

  1. Ohhara Yoshihito, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. What are the limiting factors related to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  2. Itatani Yoshiro, Akiyoshi Takashi, Kuroyanagi Hiroya, Yamakawa Keiko, Noaki Rota, Konishi Tsuyoshi, Fujimoto Yoshiya, Ueno Masashi, Oya Masatoshi, Suenaga Mitsukuni, Yamaguchi Toshiharu. Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case SURGERY TODAY. 2012.01; 42 (1): 75-79. ( PubMed, DOI )

  3. Osako M., Kawazoe Y., Mizunuma N., Gotoh T., Misaka T., Oba M., Shinozaki E., Suenaga M., Matsusaka S., Hatake K.. Cetuximab Treatment for Metastatic Colorectal Cancer With KRAS p.G130 Mutation may Improve Progression-free Survival in Japanese Patients EUROPEAN JOURNAL OF CANCER. 2011.09; 47 S395-S396.

  4. Matsusaka Satoshi, Mishima Yuji, Suenaga Mitsukuni, Terui Yasuhito, Kuniyoshi Ryoko, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating Endothelial Progenitors and CXCR4-Positive Circulating Endothelial Cells Are Predictive Markers for Bevacizumab CANCER. 2011.09; 117 (17): 4026-4032. ( PubMed, DOI )

  5. Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2011.09; 68 (3): 763-768. ( PubMed, DOI )

  6. Suenaga Mitsukuni, Matsusaka Satoshi, Ueno Masashi, Yamamoto Noriko, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients SURGERY TODAY. 2011.08; 41 (8): 1067-1074. ( PubMed, DOI )

  7. Suenaga Mitsukuni, Matsusaka Satoshi, Ueno Masashi, Yamamoto Noriko, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. 転移性結腸直腸癌患者に対する二次治療としてのFOLFIRI+bevacizumabによる有効性の予測因子(Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients) Surgery Today. 2011.08; 41 (8): 1067-1074. ( 医中誌 )

  8. Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Kuniyoshi Ryoko, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer CANCER SCIENCE. 2011.06; 102 (6): 1188-1192. ( PubMed, DOI )

  9. Suenaga Mitsukuni, Matsusaka Satoshi, Watanabe Toshiyasu, Kuboki Yasutoshi, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki, Ueno Masashi, Yamaguchi Toshiharu, Hatake Kiyohiko. How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer? ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2011.06; 7 (2): 129-135. ( PubMed, DOI )

  10. Matsusaka S., Suenaga M., Mishima Y., Takagi K., Shinozaki E., Terui Y., Mizunuma N., Hatake K.. TIE2-expressing myeloid cells as a predictive marker for bevacizumab-containing chemotherapy in metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2011.05; 29 (15):

  11. Takagi K., Chin K., Oba M., Kuboki Y., Ichimura T., Oto M., Kawazoe Y., Watanabe T., Ozaka M., Ogura M., Suenaga M., Shinozaki E., Matsusaka S., Mizunuma N., Hatake K.. EFFICACY OF PACLITAXEL FOR S-1-REFRACTORY GASTRIC CANCER (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I15.

  12. Matsusaka S., Mizunuma N., Suenaga M., Shinozaki E., Mishima Y., Terui Y., Hatake K.. PREDICTIVE POTENTIAL OF CIRCULATING ENDOTHELIAL CELLS IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING BEVACIZUMAB CONTAINING CHEMOTHERAPY (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I10.

  13. Ozaka M., Ogura M., Matsusaka S., Shinozaki E., Suenaga M., Chin K., Mizunuma N., Hatake K.. THE OPTIMUM TIME FOR SURGERY AFTER RECEIVING IMATINIB: A RETROSPECTIVE ANALYSIS OF GIST PATIENTS ACHIEVING A PARTIAL RESPONSE (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I12.

  14. Suenaga M., Matsusaka S., Watanabe T., Takagi K., Kuboki Y., Ozaka M., Shinozaki E., Chin K., Mizunuma N., Hatake K.. Coagulo-fibrinolytic activity as a predictor of efficacy in bevacizumab-combined chemotherapy in metastatic colorectal cancer patients. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  15. Suenaga M., Mizunuma N., Matsusaka S., Shinozaki E., Ogura M., Kuboki Y., Watanabe T., Ozaka M., Chin K., Hatake K.. Effect of the addition of bevacizumab to first-line FOLFOX on efficacy, including response rate, progression-free survival, and overall survival, in patients with metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  16. Suenaga M., Imada H., Nakamoto E., Matsusaka S., Watanabe T., Kawazoe Y., Shinozaki E., Chin K., Mizunuma N., Hatake K.. Optimal use of antihypertensive agents in management of bevacizumab-associated hypertension. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  17. Tsushima T., Boku N., Honma Y., Takahashi H., Ueda S., Nishina T., Kawai H., Kato S., Suenaga M., Tamura F.. Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  18. Matsusaka S., Mizunuma N., Suenaga M., Chin K., Shinozaki E., Watanabe T., Kawazoe Y., Kuboki Y., Terui Y., Hatake K.. Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  19. Matsusaka S., Chin K., Mizunuma N., Ogura M., Suenaga M., Ozaka M., Takagi K., Oba M., Mishima Y., Hatake K.. Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  20. Oba Masaru, Chin Keisho, Kawazoe Yoshimasa, Takagi Koichi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko. Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens ONCOLOGY LETTERS. 2011; 2 (2): 247-251. ( PubMed, DOI )

< 前のページ - 次のページ >

このページの先頭へ▲